Company Profile

EVEREST MED-B

1952 Biotechnology
Description

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.

Reports

This company has 4 ESG reports available.

ESG Performance Overview

Select a KPI indicator to view performance trend

KPI Indicators

A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
24 Data Points
Indicator Data Points Actions
Scope 3 GHG Emissions (Business Travel) 3
Scope 3 GHG Emissions (Fuel and Energy-related Activities (Not Included in Scope 1 or Scope 2)) 3
Total GHG Emissions Intensity (By Employee) 1
Total GHG Emissions Intensity (By Area) 1
Scope 3 GHG Emissions (Waste Generated in Operations) 2
Total GHG Emissions 3
Direct GHG Emissions (Scope 1) 2
Stationary Combustion Emissions 2
Indirect Energy Emissions (Scope 2) 2
GHG Emissions from Purchased Electricity 3
Total Other Indirect Energy Emissions (Scope 3) 2
A1.3 Hazardous Waste
4 Data Points
Indicator Data Points Actions
Total Hazardous Waste Intensity (By Employee) 1
Total Hazardous Waste Intensity (By Area) 1
Total Hazardous Waste 2
A1.4 Non-Hazardous Waste
10 Data Points
Indicator Data Points Actions
Non-Hazardous Waste Disposed 4
Non-Hazardous Waste (Office Waste) 2
Total Non-Hazardous Waste Intensity (By Employee) 2
Total Non-Hazardous Waste Intensity (By Area) 2
A1.6 Hazardous and Non-Hazardous Waste Targets
1 Data Points
Indicator Data Points Actions
Non-Hazardous Waste Intensity Reduction Percentage Compared to Last Year 1

A2.1 Energy Consumption
38 Data Points
Indicator Data Points Actions
Energy Consumption Intensity (By Employee) 3
Grid Purchased Electricity Intensity (By Area) 2
Purchased Electricity Intensity (By Area) 2
Energy Consumption Intensity (By Area) 2
Total Electricity Consumption Intensity (By Area) 2
Total Energy Consumption 4
Total Direct Energy Consumption 1
Diesel Fuel Consumption 3
Total Indirect Energy Consumption 2
Total Purchased Energy 2
Purchased Electricity 8
Purchased Steam 3
Grid Electricity Consumption 4
A2.2 Water Consumption
6 Data Points
Indicator Data Points Actions
Total Water Withdrawal 2
Total Wastewater Discharge 1
Water Consumption 2
Water Withdrawal Intensity 1
A2.4 Water Efficiency Targets
1 Data Points
Indicator Data Points Actions
Target Water Consumption Reduction Percentage Compared to Last Year 1
A2.5 Total Packaging Material Used
2 Data Points
Indicator Data Points Actions
Packaging Material Intensity (By Employee) 1
Packaging Materials Consumed 1

B1.1 Amount and Distribution of Workforce
102 Data Points
Indicator Data Points Actions
Number of Total Employees 4
Number of Male Employees 4
Number of Female Employees 4
Percentage of Male Employees 4
Percentage of Female Employees 4
Number of Full-time Employees 4
Number of Part-time Employees 4
Percentage of Full-time Employees 4
Percentage of Part-time Employees 4
Number of Employees Aged Below 30 4
Number of Employees Aged 30-50 4
Number of Employees Aged Above 50 4
Percentage of Employees Aged Below 30 3
Percentage of Employees Aged 30-50 3
Percentage of Employees Aged Above 50 3
Number of Employees in Hong Kong 1
Number of Employees in Mainland China 3
Number of Employees in Singapore 3
Number of Employees in United States 3
Number of Employees in Korea 3
Number of Employees in Indonesia 2
Percentage of Employees in Hong Kong 1
Percentage of Employees in Mainland China 3
Percentage of Employees in Singapore 2
Percentage of Employees in United States 3
Percentage of Employees in Korea 2
Percentage of Employees in Indonesia 1
Number of Senior Management Employees 4
Number of Middle Management Employees 4
Number of General Employees 1
Percentage of Senior Management Employees 4
Percentage of Middle Management Employees 4
Percentage of General Employees 1
B1.2 Employee Turnover Rate
32 Data Points
Indicator Data Points Actions
Turnover Rate of Female Employees 3
Turnover Rate of Full-time Employees 2
Turnover Rate of Male Employees 3
Turnover Rate of Part-time Employees 2
Turnover Rate of Employees Aged Below 30 3
Turnover Rate of Employees Aged 30-50 3
Turnover Rate of Employees Aged Above 50 3
Turnover Rate of Employees in Mainland China 2
Turnover Rate of Total Employees 4
Turnover Rate of Employees in Overseas 1
Turnover Rate of Employees in Singapore 1
Turnover Rate of Employees in United States 1
Turnover Rate of Senior Management Employees 2
Turnover Rate of Middle Management Employees 2

B2.1 Number and Rate of Work-related Fatalities
22 Data Points
Indicator Data Points Actions
Number of Work-related Fatalities 10
Work-related Fatalities Rate 9
Number of Fatalities as a Result of Work-related Injuries 1
Number of Fatalities as a Result of Work-related Ill Health 1
Number of Fatalities of the Last 3 Years 1
B2.2 Lost Days Due to Work Injury
10 Data Points
Indicator Data Points Actions
Lost Days Due to Work-related Injuries 10

B3.1 The Percentage of Employees Trained
20 Data Points
Indicator Data Points Actions
Percentage of Employees Trained 4
Percentage of Trained Male Employees 3
Percentage of Trained Female Employees 4
Percentage of Trained Senior Management 4
Percentage of Trained Middle Management 3
Percentage of Trained General Employees 2
B3.2 Average Training Hours Completed per Employee
25 Data Points
Indicator Data Points Actions
Total Training Hours 3
Average Training Hours per Employee 3
Average Training Hours (Male) 4
Average Training Hours (Female) 4
Average Training Hours (Senior Management) 4
Average Training Hours (Middle Management) 3
Average Training Hours (General Staff) 2
Average Training Hours (General Employees) 2

B5.1 Number of Suppliers by Geographical Region
2 Data Points
Indicator Data Points Actions
Number of Total Suppliers 1
Number of Suppliers in Mainland China 1

General
2 Data Points
Indicator Data Points Actions
Number of Employees in France 1
Percentage of Employees in France 1

ESG Reports

Year Report Title Publication Date Raw KPIs Standard KPIs Processed Actions
2024 2024 Environmental, Social and Governance Report 2025-04-24 125 89 Yes
2023 2023 Environmental, Social and Governance Report 2024-04-24 118 81 Yes
2022 2022 Environmental, Social and Governance Report 2023-04-20 129 73 Yes
2021 2021 Environmental, Social and Governance Report 2022-05-25 63 58 Yes